Raymond James Financial
OCUL icon

Raymond James Financial’s Ocular Therapeutix OCUL Stock Holding History

Raymond James Financial’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.46M Buy
963,316
+103,831
+12% +$941K ﹤0.01% 2210
2026
Q1 		$7.28M Buy
859,485
+17,298
+2% +$165K ﹤0.01% 2277
2025
Q4 		$10.2M Sell
842,187
-169,782
-17% -$2.06M ﹤0.01% 1944
2025
Q3 		$11.8M Buy
1,011,969
+127,588
+14% +$1.53M ﹤0.01% 1789
2025
Q2 		$8.21M Buy
884,381
+520,138
+143% +$4.07M ﹤0.01% 2020
2025
Q1 		$2.67M Buy
364,243
+162,620
+81% +$1.25M ﹤0.01% 2786
2024
Q4 		$1.72M Buy
+201,623
New +$1.97M ﹤0.01% 3068

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Raymond James Financial's OCUL Position: Q2 2026 in Review

Raymond James Financial increased its Ocular Therapeutix (OCUL) stake by 12% in Q2 2026, buying an estimated $941K and bringing the position to 963,316 shares worth $9.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2210.

Raymond James Financial first reported a position in OCUL in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.8M in Q3 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Raymond James Financial held 963,316 shares of Ocular Therapeutix worth $9.46M as of Q2 2026.
  • Raymond James Financial bought 103,831 Ocular Therapeutix shares in Q2 2026, an estimated $941K.
  • Ocular Therapeutix made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2210 holding.
  • Raymond James Financial first reported a position in Ocular Therapeutix in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Ocular Therapeutix position peaked at $11.8M in Q3 2025.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.